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Anti-angiogenic drugs, used for cancer treatment, target blood-vessel formation 
in tumours. Two studies show that such drugs can reduce the efficiency of other 




Tumour growth depends on the concomitant outgrowth of an extended vascular 
network to ensure a continuous supply of oxygen and nutrients. Blocking the formation 
of new blood vessels with anti-angiogenic therapy is currently used to treat certain types 
of cancer. For its central role in promoting angiogenesis, vascular endothelial growth 
factor (VEGF) is the main target of the currently approved anti-angiogenic drugs. While 
several aspects of their mechanism of anti-tumour action are still unknown, evidence is 
slowly unravelling their concealed details and exposing their limitations. Recently, two 
decisive studies uncovered some of the limitations of anti-angiogenics to reveal that 
these therapies decrease chemotherapeutic drug delivery to tumours which could hinder 
their therapeutic benefits, and also describe tumour adaptation to therapy involving 
accumulation of more aggressive precursor tumour cells. 
The mechanism how VEGF-blocking anti-angiogenic inhibitors provide 
additional anti-tumour effects when combined with cytotoxic drugs has been an 
unresolved mystery since the early positive results on combination trials
1
. The most 
widespread explanation, the “vascular normalization” theory was proposed by Rakesh K. 
Jain in 2001, where anti-angiogenic therapy induces a structural and functional change 
in the aberrant tumor vasculature to convert it to more normal characteristics, allowing 
for increased perfusion that consequently improves drug penetration and enhances 
efficacy of cytotoxic drugs
2,3
. Recently, Van der Veldt et al. performed a clinical study 
on drug perfusion, uptake and retention in 10 advanced-stage non-small cell lung cancer 
(NSCLC) patients using radiolabeled drug tracing by PET imaging. Their specific and 
high sensitivity detection of [11C]Docetaxel chemotherapeutic drug clearly 
demonstrated that inhibition of VEGF with Bevacizumab induced a fast and sustained 
decrease not only in water perfusion but also in drug perfusion and uptake in tumors
4
. 
These results are in contraposition to previous clinical studies in rectal cancer and 
glioblastoma (GBM) patients where vascular normalization was documented and 
increased drug uptake (by glucose tracer) was suggested after Bevacizumab treatment
5,6
. 
Tumour type heterogeneity in vascularity and responses to anti-angiogenic therapies 
could underlie these discrepancies between GBM, rectal cancer and NSCLC, as anti-
angiogenic therapies can differentially alter vascular functional characteristics such as 





 ...). In any case, learning that at least in NSCLC patients anti-angiogenic drugs 
are not able to improve drug delivery to tumours but rather have the opposite effect, 
exposes a relevant limitation of combination treatments using anti-VEGF and 
chemotherapy or other blood-distributed anti-cancer drug. Indeed, this could be the 
cause of the modest benefits of these combination therapies in NSCLC but also in other 
tumour types
8
. Therefore, this potential drawback will have to be solved in the future by 
optimizing the scheduling of these therapeutic agents, for example, with sequential 
scheduling of chemotherapy or other targeted drugs followed by anti-angiogenics. 
Another recent contribution on the limits of anti-angiogenic therapies has 
exposed the amplitude of tumour plasticity and high capacity of adaptation to these 
therapies. Tumours have long been shown to have remarkable plasticity and adaptability 
to chemotherapy and radiation, but it was initially postulated that anti-angiogenics 
would not induce the same adaptation and selection because they target endothelial cells 
rather than tumour cells
9
. Nevertheless, pre-clinical and clinical evidence has revealed 
that tumour adaptation and resistance to anti-angiogenic therapy does indeed occur, 
mostly due to tumour cell adaptation to therapy
10,11
.  
In this sense, Conley et al. have gone further to document that in animal models 
of Breast Cancer tumour adaptation to anti-angiogenics includes a hypoxia-driven 
accumulation of progenitor cells that confer these tumours with more aggressive 
characteristics
12
. As broadly reported, targeting VEGF ligand (Bevacizumab) or its main 
receptors (Sunitinib) were found to activate a hypoxia response programme, but they 
further reveal a subsequent induction of the Akt/β-catenin pathway which is implicated 
in the regulation of progenitor cells in breast cancer. To identify this population, the 
authors use aldehyde dehydrogenase (ALDH), a metabolic enzyme that converts 
aldehydes from many different origins (carbohydrates, lipids and even alcohol) to 
carboxylic derivatives. While ALDH enzymatic activity was recently described as a 
precursor cell marker in tumours
13
, it remains to be determined whether accumulation of 
cells with this enzymatic activity could be caused by atypical accumulation of 
metabolites driven by hypoxia. 
In any case, while a selection for progenitor cells has been described in several tumour 
types treated with classical chemotherapy due to their higher resistance to these agents
14
, 
similar effects with anti-angiogenic drugs had only been scarcely described in 
glioblastomas under combination therapies
15
. Thus, this study signifies a major 
advancement in understanding the benefits and limitations of anti-angiogenic therapies. 
Furthermore, it delineates a possible cellular and molecular mechanism for the 
previously reported tumour aggressiveness and metastatization effects of anti-
angiogenic therapies in several animal models
16,17
. Indeed, the specific tumour cell 
populations that are selected or accumulated after anti-angiogenics in this study have 
been described to have enhanced tumour formation capabilities and a high metastatic 
potential
18
. Thus, the hypoxia-induced, Akt/β-Catenin mediated activation of these 
specific tumour cell populations could explain the enhanced tumour aggressiveness and 
metastatic potential observed after anti-angiogenic therapies in different tumour types. 
Therefore, the selection or accumulation of these more aggressive tumour populations is 
yet another limitation of anti-angiogenic therapies and will have to be addressed 
mechanistically and therapeutically in order to improve their effectiveness. One 
possibility would be the use of combinatorial treatments of anti-angiogenic therapies 
together with anti-hypoxia response agents or anti-Akt/β-catenin drugs; or the use 
pleiotropic recombinant molecules that can exert dual (or multiple) anti-cancer effects 
by targeting angiogenesis together with blocking invasion and impeding metastasis, 




These two recent contributions on the limitations of anti-angiogenic therapies further 
emphasize the need of a carefully balanced evaluation of the benefits and limitations of 
anti-angiogenic therapies. But even more importantly, they warrant further studies on 
these pernicious aspects in order to improve effectiveness and extend the therapeutic 
benefits of anti-angiogenic agents. This could be achieved by sequential scheduling of 
chemotherapy and anti-angiogenics, smarter combinations of anti-angiogenic drugs with 
others targeting progenitor cell pathways or new multi-targeting with pleiotropic 
molecules blocking angiogenesis and their limitations. Overall, despite many open 
questions, there is hope that an understanding of the limitations of anti-angiogenic 
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FIGURE 1:  Some drawbacks of anticancer therapies.  a, By affecting blood vessel 
formation, anti-angiogenic drugs can enhance the efficacy of blood-distributed cytotoxic 
agents that inhibit the growth of cancer cells. However, some tumour cells known as 
cancer precursor cells are particularly dangerous because they can be more resistant to 
cytotoxic agents than the rest of the tumour cells, and they can spread to other organs 
and start new tumours. b,c, Anti-angiogenic therapy, however, can have negative effects 
too. b, It can reduce the distribution of cytotoxic agents in the tumour, and hence their 
efficacy. Van der Veldt et al.1 report an example of such undesirable effect in patients 
with non-small cell lung cancer. c, Moreover, anti-angiogenic drugs can, by reducing 
oxygen levels within the tumour, induce the accumulation of more aggressive cells that 
— like cancer precursor cells — have increased capacity to spread to other organs. 
Conley et al.2 document this phenomenon in mouse models of breast cancer. 
ACKNOWLEDGMENTS 
 The author would like to thank Mariona Graupera and Francesc Viñals for 
critical reading of the manuscript and helpful suggestions. The author’s work is 
supported by research grants from MICINN (SAF2009-08375, RTICC-RD2006-0092) 
and AGAUR (SGR681) from Spain.  
 
REFERENCES 
1. Hurwitz, H. I. et al. Bevacizumab in combination with fluorouracil and 
leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin 
Oncol 23, 3502-8 (2005). 
2. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new 
paradigm for combination therapy. Nat Med 7, 987-9 (2001). 
3. Jain, R. K. Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science 307, 58-62 (2005). 
4. Van der Veldt, A. A. et al. Rapid Decrease in Delivery of Chemotherapy to 
Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-
Angiogenic Drugs. Cancer Cell 21, 82-91. 
5. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody 
bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-7 
(2004). 
6. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, 
normalizes tumor vasculature and alleviates edema in glioblastoma patients. 
Cancer Cell 11, 83-95 (2007). 
7. Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the 
normal adult microvasculature. Am J Physiol Heart Circ Physiol 290, H560-76 
(2006). 
8. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-
small-cell lung cancer. N Engl J Med 355, 2542-50 (2006). 
9. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Antiangiogenic therapy 
of experimental cancer does not induce acquired drug resistance. Nature 390, 
404-7 (1997). 
10. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat 
Rev Cancer 8, 592-603 (2008). 
11. Rini, B. I. & Atkins, M. B. Resistance to targeted therapy in renal-cell 
carcinoma. Lancet Oncol 10, 992-1000 (2009). 
12. Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via 
the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 
13. Ginestier, C. et al. ALDH1 is a marker of normal and malignant human 
mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 
555-67 (2007). 
14. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. 
Cell 131, 1109-23 (2007). 
15. Folkins, C. et al. Anticancer therapies combining antiangiogenic and tumor cell 
cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft 
tumors. Cancer Res 67, 3560-4 (2007). 
16. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of 
tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-
31 (2009). 
17. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent 
inhibitor of tumor angiogenesis. Cancer Cell 15, 232-9 (2009). 
18. Charafe-Jauffret, E. et al. Aldehyde dehydrogenase 1-positive cancer stem cells 
mediate metastasis and poor clinical outcome in inflammatory breast cancer. 
Clin Cancer Res 16, 45-55. 
19. Casazza, A. et al. Tumour growth inhibition and anti-metastatic activity of a 
mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med. 
 
 
